← Leaderboards
Robert T O'Donnell
University Of California Davis
$706,327
Attributed
$706,327
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $266.4K · FY2006–15$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$706,327 · 2
VA$0 · 1
By mechanism
R21$525,818 · 1
P01$180,509 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Davis
Same institution · by research overlap
- Claude F. Meares$5,274,336
- Gerald L Denardo$3,030,924
- Sally J Denardo$2,893,757
- Christine L Hartmann-Siantar$706,984
- Carol M. Richman$180,509
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionBinding (Molecular Function)Monoclonal AntibodiesRoche Brand Of RituximabToxic EffectProgramsClinical TrialsMalignant NeoplasmsPharmaceutical PreparationsRituximabClinical ResearchAntibodiesApoptoticApoptosisCancer EtiologyCd22 GeneBaseDrug KineticsCellsCessation Of LifeCancer CellBortezomibB-LymphocytesBlood
Grant awards (9)
Immunoliposomal Therapy of non-Hodgkin's Lymphoma$0
I01 · FY2015 · VA · contact PI
Immunoliposomal Therapy of non-Hodgkin's Lymphoma$0
I01 · FY2014 · VA · contact PI
Immunoliposomal Therapy of non-Hodgkin's Lymphoma$0
I01 · FY2013 · VA · contact PI
Immunoliposomal Therapy of non-Hodgkin's Lymphoma$0
I01 · FY2012 · VA · contact PI
PhaseI/II Clinical Trial of hHB22.7 anti-CD22 Monoclonal Antibody for Lymphoma$259,395
R21 · FY2007 · CA · contact PI
PhaseI/II Clinical Trial of hHB22.7 anti-CD22 Monoclonal Antibody for Lymphoma$266,423
R21 · FY2006 · CA · contact PI
Combined modality radioimmunotherapy for nonHodgkins lymphoma$0
P01 · FY2002 · CA
Combined modality radioimmunotherapy for nonHodgkins lymphoma$0
P01 · FY2001 · CA
Combined modality radioimmunotherapy for nonHodgkins lymphoma$180,509
P01 · FY2000 · CA